Nuvation Bio Inc is a biotechnology company focused on the development of innovative therapies to treat cancer and other serious diseases
By leveraging advanced scientific expertise and cutting-edge technologies, Nuvation Bio aims to create novel drug candidates that address unmet medical needs. The company's efforts center around its commitment to precision medicine, and it conducts extensive research to understand the underlying mechanisms of diseases, which informs the design of targeted treatment options. Through collaboration with partners in the biopharmaceutical industry, Nuvation Bio seeks to bring transformative therapies to patients while pushing the boundaries of scientific knowledge in the field of oncology.
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months By Doug Young
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.
Shares of LuxUrban Hotels Inc. (NASDAQLUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of Westport Fuel Systems Inc. (NASDAQWPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday. Shares of Esperion Therapeutics, Inc. (NASDAQESPR) rose sharply in today’s pre-market trading.
